The Emerging Parkinson's Disease Oxylipin-Ome

Area of Science:

• Neuroscience
• Biochemistry
• Metabolomics

Background:

• Parkinson disease (PD) is increasingly viewed as a complex proteinopathy and lipidopathy.
• This paradigm has evolved to a fatty acid (FA)-opathy, highlighting dysregulated FA metabolism in PD's lipid dysfunction.
• FA dysfunction can disrupt alpha-synuclein (αS)-membrane interactions, affecting αS localization, conformation, and aggregation.

Purpose of the Study:

• To explore the impact of PD-associated FA dyshomeostasis on the bioactive oxylipin-ome.
• To investigate potential PD oxylipin-ome signatures based on human PD studies.
• To assess oxylipins and their precursors as novel therapeutic targets for PD.

Main Methods:

• Review of human PD studies examining oxylipin profiles, precursor polyunsaturated fatty acids (PUFAs), and oxylipin biosynthetic enzymes.
• Analysis of existing literature on FA metabolism, αS interactions, and PD.
• Synthesis of findings to propose a role for the oxylipin-ome in PD pathogenesis.

Main Results:

• PD is characterized by disrupted oxylipin and oxylipin precursor PUFA abundance.
• Higher PUFA intake is associated with reduced PD risk and progression.
• Cyclooxygenase (COX) inhibition correlates with lower PD incidence.

Conclusions:

• The oxylipin-ome likely plays a significant role in Parkinson disease.
• Oxylipin metabolism represents a potential novel target for developing PD biomarkers.
• Targeting oxylipin metabolism may offer a strategy for disease-modifying therapeutics in PD.